WINTON GROUP Ltd Buys 17,730 Shares of Vericel Corporation $VCEL

WINTON GROUP Ltd lifted its stake in Vericel Corporation (NASDAQ:VCEL) by 104.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,766 shares of the biotechnology company’s stock after acquiring an additional 17,730 shares during the quarter. WINTON GROUP Ltd’s holdings in Vericel were worth $1,094,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of VCEL. William Blair Investment Management LLC boosted its position in Vericel by 90.3% during the third quarter. William Blair Investment Management LLC now owns 2,210,929 shares of the biotechnology company’s stock valued at $69,578,000 after purchasing an additional 1,048,864 shares during the last quarter. Champlain Investment Partners LLC increased its position in shares of Vericel by 62.5% during the 2nd quarter. Champlain Investment Partners LLC now owns 997,291 shares of the biotechnology company’s stock worth $42,435,000 after purchasing an additional 383,498 shares during the last quarter. Aberdeen Group plc raised its stake in shares of Vericel by 159.5% during the 3rd quarter. Aberdeen Group plc now owns 542,866 shares of the biotechnology company’s stock worth $17,084,000 after purchasing an additional 333,649 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Vericel in the 2nd quarter valued at approximately $9,713,000. Finally, Frontier Capital Management Co. LLC boosted its holdings in shares of Vericel by 74.3% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 398,960 shares of the biotechnology company’s stock valued at $16,976,000 after buying an additional 170,006 shares during the last quarter.

Analysts Set New Price Targets

VCEL has been the subject of several analyst reports. HC Wainwright boosted their target price on shares of Vericel from $60.00 to $64.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Truist Financial cut their price target on shares of Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Zacks Research lowered shares of Vericel from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Finally, Wall Street Zen cut shares of Vericel from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.00.

Vericel Stock Performance

NASDAQ VCEL opened at $32.88 on Thursday. The stock has a market cap of $1.67 billion, a PE ratio of 106.06 and a beta of 1.22. The firm has a 50-day moving average of $36.61 and a 200-day moving average of $36.01. Vericel Corporation has a 52-week low of $29.24 and a 52-week high of $48.74.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, meeting analysts’ consensus estimates of $0.45. The business had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. Vericel had a net margin of 5.98% and a return on equity of 5.17%. Vericel’s quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.38 EPS. As a group, analysts predict that Vericel Corporation will post 0.14 EPS for the current fiscal year.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.